Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review

Arthritis Care and Research

Volumn 68, Issue 8, 2016, Pages 1078-1088

  Desai, Rishi J ^a   Thaler, Kylie J ^b   Mahlknecht, Peter ^b   Gartlehner, Gerald ^b   McDonagh, Marian S ^c   Mesgarpour, Bita ^d   Mazinanian, Alireza ^b   Glechner, Anna ^b   Gopalakrishnan, Chandrasekar ^a   Hansen, Richard A ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANUBE UNIVERSITY KREMS   (Austria)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB;

ADVERSE OUTCOME; ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL ARTHRITIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; INFECTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORTALITY; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITATIVE RESEARCH; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SKIN INFECTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84978879462     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22815     Document Type: Article

References (54)

1. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88.
2. Theodorou AA, Johnson KM, Szychowski JA. 2009 drug utilization and cost trends: tumor necrosis factor inhibitors. Am J Pharm Benefits 2010;2:387–92. [Patternmatch].
3. Donahue K, Jonas D, Hansen R, Roubey R, Jonas B, Lux L, et al. Drug therapy for rheumatoid arthritis in adults: an update. Rockville (MD): Agency for Healthcare Research and Quality; 2012.
4. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 2015;148:344–54.
5. Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord 2014;15:26.
6. Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014;170:274–303.
7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.
8. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787–96.
9. Hochberg MC, Berry S, Broglio K, Rosenblatt L, Nadkarni A, Trivedi D, et al. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. Curr Med Res Opin 2013;29:1213–22.
10. Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann Pharmacother 2012;46:1491–505.
11. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794.
12. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20:21–35.
13. Khan KS, ter Riet G, Popay J, Nixon J, Kleijnen J. Undertaking systematic reviews of research on effectiveness CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4.2. University of York: NHS Centre for Reviews and Dissemination. 2001.
14. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
15. Berkman ND, Lohr KN, Ansari M, McDonagh M, Balk E, Whitlock E, et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update. Rockville (MD): Agency for Healthcare Research and Quality; 2008.
16. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012;61:229–34.
17. Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015;386:552–61.
18. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118–28.
19. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096–103.
20. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86–94.
21. Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;71:1820–6.
22. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600–6.
23. Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol 2013;11:826–31.
24. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274–9.
25. Yeung H, Wan J, van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013;68:64–72.
26. Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 2013;40:1008–13.
27. Esposito M, Gisondi P, Cassano N, Ferrucci G, del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013;169:666–72.
28. Simard JF, Neovius M, Askling J, for the ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012;64:3502–10.
29. Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, et al. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf 2012;21:1311–20.
30. Tarkiainen M, Tynjala P, Vahasalo P, Lahdenne P. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford) 2015;54:1170–6.
31. Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy. Yonsei Med J 2014;55:442–8.
32. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013;72:229–34.
33. Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum 2012;42:223–33.
34. Lampropoulos CE, Orfanos P, Bournia VK, Karatsourakis T, Mavragani C, Pikazis D, et al. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol 2015;33:216–24.
35. Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 2015;42:372–8.
36. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH. Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011;38:2218–23.
37. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013;72:37–42.
38. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:522–8.
39. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015;74:1212–7.
40. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887–95.
41. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48:1364–71.
42. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009;301:737–44.
43. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560–8.
44. Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, et al. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis 2014;17:9–19.
45. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886–95.
46. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180–9.
47. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
48. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 2014;73:1942–8.
49. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616–23.
50. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:1810–4.
51. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1431–9.
52. Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869–74.
53. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305–11.
54. Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, et al. Association between anti-TNF-(α) therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 2013;22:394–402.